Xing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xing Li has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Min Long
Department of Endocrinology, The First Affiliated Hospital (Southwest Hospital) of Army Medical University
7 shared publications - Cong-Yi Wang
Department of Endocrinology, Metabolic and Chronic Disease Science Innovation Center, Translational Research of Diabetes Key Laboratory of Chongqing, The Second Affiliated Hospital of Army Medical University, Chongqing, 400037, China
6 shared publications - Jiaqing Shao
Department of Endocrinology, Jinling Clinical Medical College, Nanjing Medical University, Nanjing, China
4 shared publications Ling Zhou
Department of Endocrinology Southwest Hospital, Army Medical University (Third Military Medical University) Chongqing China
3 shared publicationsRufei Shen
Department of Endocrinology, Translational Research Key Laboratory for Diabetes, Xinqiao Hospital, Army Medical University, Chongqing, China
3 shared publicationsShaodong Guo
Department of Nutrition and Food Science, Texas A&M University, TX 77843, USA
3 shared publications
Latest Publications
- Open Access
- 15 October 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (10) , 111548
Serum alpha-1-microglobulin as a predictor of multiple complications in type 2 diabetes mellitus patients
BACKGROUND Poor glycaemic control in patients with type 2 diabetes mellitus (T2DM) is often accompanied by multiple complications, including diabetic nephropathy (DN), diabetic retinopathy (DR), diabetic peripheral neuropathy (DPN), and cardiac structural abnormality left ventricular hypertrophy (LVH). Early identification of high-risk populations for these complications and the implementation of intervention measures are crucial for improving patient outcomes. Serum alpha-1-microglobulin (α1-MG), a multifunctional protein synthesized by the liver and lymphocytes, has been considered a potential biomarker of diabetes-related diseases in recent years. AIM To investigate the associations of serum α1-MG with DN, DR, DPN, and LVH in T2DM patients and its predictive value. METHODS This retrospective study included 5045 T2DM patients. The study participants were stratified into quartiles according to their serum α1-MG levels. Multivariate logistic regression, restricted cubic spline, and explainable machine learning models were employed for risk assessment and feature importance evaluation. RESULTS Increased α1-MG levels were observed in patients with DN, DR, DPN, and LVH (all P < 0.001). Multivariate logistic regression revealed that each standard deviation increase in α1-MG was associated with an 84% increase in DN risk (OR: 1.84, 95%CI: 1.62-2.10, P < 0.001), a 17% increase in DR risk (OR: 1.17, 95%CI: 1.07-1.28, P < 0.001), a 14% increase in DPN risk (OR: 1.14, 95%CI: 1.03-1.27, P = 0.014), and a 28% increase in LVH risk (OR: 1.28, 95%CI: 1.18-1.38, P < 0.001). Subgroup analyses and machine learning confirmed the associations of elevated α1-MG with these complications in T2DM patients. CONCLUSION Elevated serum α1-MG levels were independently associated with increased risks of DN, DR, DPN, and LVH in T2DM patients, suggesting its potential as a predictive biomarker.
- 15 October 2025
- Published by Baishideng Publishing Group Inc. in World Journal of Diabetes
- Vol. 16 (10) , 111548
Open AccessSerum alpha-1-microglobulin as a predictor of multiple complications in type 2 diabetes mellitus patients
BACKGROUND Poor glycaemic control in patients with type 2 diabetes mellitus (T2DM) is often accompanied by multiple complications, including diabetic nephropathy (DN), diabetic retinopathy (DR), diabetic peripheral neuropathy (DPN), and cardiac structural abnormality left ventricular hypertrophy (LVH). Early identification of high-risk populations for these complications and the implementation of intervention measures are crucial for improving patient outcomes. Serum alpha-1-microglobulin (α1-MG), a multifunctional protein synthesized by the liver and lymphocytes, has been considered a potential biomarker of diabetes-related diseases in recent years. AIM To investigate the associations of serum α1-MG with DN, DR, DPN, and LVH in T2DM patients and its predictive value. METHODS This retrospective study included 5045 T2DM patients. The study participants were stratified into quartiles according to their serum α1-MG levels. Multivariate logistic regression, restricted cubic spline, and explainable machine learning models were employed for risk assessment and feature importance evaluation. RESULTS Increased α1-MG levels were observed in patients with DN, DR, DPN, and LVH (all P < 0.001). Multivariate logistic regression revealed that each standard deviation increase in α1-MG was associated with an 84% increase in DN risk (OR: 1.84, 95%CI: 1.62-2.10, P < 0.001), a 17% increase in DR risk (OR: 1.17, 95%CI: 1.07-1.28, P < 0.001), a 14% increase in DPN risk (OR: 1.14, 95%CI: 1.03-1.27, P = 0.014), and a 28% increase in LVH risk (OR: 1.28, 95%CI: 1.18-1.38, P < 0.001). Subgroup analyses and machine learning confirmed the associations of elevated α1-MG with these complications in T2DM patients. CONCLUSION Elevated serum α1-MG levels were independently associated with increased risks of DN, DR, DPN, and LVH in T2DM patients, suggesting its potential as a predictive biomarker.
- Open Access
- 19 August 2024
- Published by Wiley in Journal of Diabetes
- Vol. 16 (8) , e13599
Association between serum β2‐microglobulin and left ventricular hypertrophy in patients with type 2 diabetes mellitus: A cross‐sectional study
Background: Beta 2‐microglobulin (β2‐MG) is a component of the class I major histocompatibility complex (MHCI) and has recently been reported to be involved in type 2 diabetes mellitus (T2DM) and cardiovascular disease. However, the association of β2‐MG with left ventricular hypertrophy (LVH) in T2DM patients remains unknown. This study aims to investigate the correlation between serum β2‐MG and LVH in T2DM patients.Methods: The retrospective analysis included 4602 eligible T2DM patients, divided into LVH and non‐LVH groups based on echocardiography results. Serum β2‐MG levels were measured, and participants were categorized into four groups (Q1–Q4) by their serum β2‐MG quartile. The relationship of serum β2‐MG level with LVH was evaluated using logistic regression, restricted cubic spline (RCS), subgroup analysis, and machine learning.Results: The prevalence of LVH in T2DM patients was 31.12%. Each standard deviation increase in serum β2‐MG level corresponded to a 1.17‐fold increase in the prevalence of LVH [OR = 1.17, (95% CI: 1.05–1.31); p = 0.006]. When considering β2‐MG as a categorical variable (quartile), Q3 [OR = 1.36, (95% CI: 1.09–1.69); p = 0.007] and Q4 [OR = 1.77, (95% CI: 1.36–2.31); p < 0.001] had a significantly higher prevalence of LVH than Q1. RCS analysis found a nonlinear association between β2‐MG and LVH prevalence (p for nonlinearity <0.05). Additionally, machine learning results confirmed the importance of β2‐MG for LVH in T2DM patients.Conclusion: Elevated serum β2‐MG levels were likely to be associated with an increased prevalence of LVH in T2DM patients, suggesting its potential role in LVH development. image
- 19 August 2024
- Published by Wiley in Journal of Diabetes
- Vol. 16 (8) , e13599
Open AccessAssociation between serum β2‐microglobulin and left ventricular hypertrophy in patients with type 2 diabetes mellitus: A cross‐sectional study
Background: Beta 2‐microglobulin (β2‐MG) is a component of the class I major histocompatibility complex (MHCI) and has recently been reported to be involved in type 2 diabetes mellitus (T2DM) and cardiovascular disease. However, the association of β2‐MG with left ventricular hypertrophy (LVH) in T2DM patients remains unknown. This study aims to investigate the correlation between serum β2‐MG and LVH in T2DM patients.Methods: The retrospective analysis included 4602 eligible T2DM patients, divided into LVH and non‐LVH groups based on echocardiography results. Serum β2‐MG levels were measured, and participants were categorized into four groups (Q1–Q4) by their serum β2‐MG quartile. The relationship of serum β2‐MG level with LVH was evaluated using logistic regression, restricted cubic spline (RCS), subgroup analysis, and machine learning.Results: The prevalence of LVH in T2DM patients was 31.12%. Each standard deviation increase in serum β2‐MG level corresponded to a 1.17‐fold increase in the prevalence of LVH [OR = 1.17, (95% CI: 1.05–1.31); p = 0.006]. When considering β2‐MG as a categorical variable (quartile), Q3 [OR = 1.36, (95% CI: 1.09–1.69); p = 0.007] and Q4 [OR = 1.77, (95% CI: 1.36–2.31); p < 0.001] had a significantly higher prevalence of LVH than Q1. RCS analysis found a nonlinear association between β2‐MG and LVH prevalence (p for nonlinearity <0.05). Additionally, machine learning results confirmed the importance of β2‐MG for LVH in T2DM patients.Conclusion: Elevated serum β2‐MG levels were likely to be associated with an increased prevalence of LVH in T2DM patients, suggesting its potential role in LVH development. image
- Open Access
- 1 April 2023
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 16 (4) , 104588
Design, synthesis, bioactivity and mechanism of action of novel myricetin derivatives containing amide and hydrazide
- 1 April 2023
- Published by Scientific Scholar in Arabian Journal of Chemistry
- Vol. 16 (4) , 104588
Open AccessDesign, synthesis, bioactivity and mechanism of action of novel myricetin derivatives containing amide and hydrazide
- Open Access
- 31 May 2022
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 46 (3) , 451-463
Identification of Key Genes and Pathways in Peripheral Blood Mononuclear Cells of Type 1 Diabetes Mellitus by Integrated Bioinformatics Analysis
Background: The onset and progression of type 1 diabetes mellitus (T1DM) is closely related to autoimmunity. Effective monitoring of the immune system and developing targeted therapies are frontier fields in T1DM treatment. Currently, the most available tissue that reflects the immune system is peripheral blood mononuclear cells (PBMCs). Thus, the aim of this study was to identify key PBMC biomarkers of T1DM.Methods: Common differentially expressed genes (DEGs) were screened from the Gene Expression Omnibus (GEO) datasets GSE9006, GSE72377, and GSE55098, and PBMC mRNA expression in T1DM patients was compared with that in healthy participants by GEO2R. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein-protein interaction (PPI) network analyses of DEGs were performed using the Cytoscape, DAVID, and STRING databases. The vital hub genes were validated by reverse transcription-polymerase chain reaction using clinical samples. The disease-gene-drug interaction network was built using the Comparative Toxicogenomics Database (CTD) and Drug Gene Interaction Database (DGIdb).Results: We found that various biological functions or pathways related to the immune system and glucose metabolism changed in PBMCs from T1DM patients. In the PPI network, the DEGs of module 1 were significantly enriched in processes including inflammatory and immune responses and in pathways of proteoglycans in cancer. Moreover, we focused on four vital hub genes, namely, chitinase-3-like protein 1 (CHI3L1), C-X-C motif chemokine ligand 1 (CXCL1), matrix metallopeptidase 9 (MMP9), and granzyme B (GZMB), and confirmed them in clinical PBMC samples. Furthermore, the disease-gene-drug interaction network revealed the potential of key genes as reference markers in T1DM.Conclusion: These results provide new insight into T1DM pathogenesis and novel biomarkers that could be widely representative reference indicators or potential therapeutic targets for clinical applications.
- 31 May 2022
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 46 (3) , 451-463
Open AccessIdentification of Key Genes and Pathways in Peripheral Blood Mononuclear Cells of Type 1 Diabetes Mellitus by Integrated Bioinformatics Analysis
Background: The onset and progression of type 1 diabetes mellitus (T1DM) is closely related to autoimmunity. Effective monitoring of the immune system and developing targeted therapies are frontier fields in T1DM treatment. Currently, the most available tissue that reflects the immune system is peripheral blood mononuclear cells (PBMCs). Thus, the aim of this study was to identify key PBMC biomarkers of T1DM.Methods: Common differentially expressed genes (DEGs) were screened from the Gene Expression Omnibus (GEO) datasets GSE9006, GSE72377, and GSE55098, and PBMC mRNA expression in T1DM patients was compared with that in healthy participants by GEO2R. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and protein-protein interaction (PPI) network analyses of DEGs were performed using the Cytoscape, DAVID, and STRING databases. The vital hub genes were validated by reverse transcription-polymerase chain reaction using clinical samples. The disease-gene-drug interaction network was built using the Comparative Toxicogenomics Database (CTD) and Drug Gene Interaction Database (DGIdb).Results: We found that various biological functions or pathways related to the immune system and glucose metabolism changed in PBMCs from T1DM patients. In the PPI network, the DEGs of module 1 were significantly enriched in processes including inflammatory and immune responses and in pathways of proteoglycans in cancer. Moreover, we focused on four vital hub genes, namely, chitinase-3-like protein 1 (CHI3L1), C-X-C motif chemokine ligand 1 (CXCL1), matrix metallopeptidase 9 (MMP9), and granzyme B (GZMB), and confirmed them in clinical PBMC samples. Furthermore, the disease-gene-drug interaction network revealed the potential of key genes as reference markers in T1DM.Conclusion: These results provide new insight into T1DM pathogenesis and novel biomarkers that could be widely representative reference indicators or potential therapeutic targets for clinical applications.
- Open Access
- 11 February 2022
- Published by Wiley in Mediators of Inflammation
- Vol. 2022, 1-16
Plasma Diaphanous Related Formin 1 Levels Are Associated with Altered Glucose Metabolism and Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Case Control Study
Background. Diaphanous related formin 1 (DIAPH1) is a novel component of advanced glycation end product (AGE) signal transduction that was recently found to participate in diabetes-related disorders, obesity, and androgen hormones. We investigated whether plasma DIAPH1 levels were a potential prognostic predictor for polycystic ovary syndrome (PCOS). Methods. The levels of circulating plasma DIAPH1 and indicators of glucose, insulin, lipid metabolism, liver enzymes, kidney function, sex hormones, and inflammation were measured in 75 patients with PCOS and 77 healthy participants. All of the participants were divided into normal-weight (NW) and overweight/obese (OW) subgroups. Statistical analyses were performed with R studio. Results. PCOS patients manifested hyperandrogenism, increased luteinizing hormone/follicle-stimulating hormone (LH/FSH), and accumulated body fat and insulin resistance. Plasma DIAPH1 levels were significantly decreased in women with PCOS compared to control participants, and DIAPH1 levels were distinctly reduced in OW PCOS compared to OW control subjects ( ). DIAPH1 levels correlated with fasting blood glucose (FBG), total cholesterol (TC), the homeostasis model assessment of β-cell function (HOMA-β), and LH/FSH in all participants (FBG: , ; TC: , ; HOMA-β: , ; LH/FSH: , ). Multivariate logistic regression analysis revealed that plasma DIAPH1 levels were an independent risk factor for PCOS. A model containing DIAPH1, BMI, FBG, and testosterone was constructed to predict the risk of PCOS, with a sensitivity of 92.0% and a specificity of 80.9%. A nomogram was constructed to facilitate clinical diagnosis. Conclusions. These findings suggest the association of plasma DIAPH1 with glucose metabolism, insulin resistance, and sex hormones and support DIAPH1 as a potential predictive factor for PCOS.
- 11 February 2022
- Published by Wiley in Mediators of Inflammation
- Vol. 2022, 1-16
Open AccessPlasma Diaphanous Related Formin 1 Levels Are Associated with Altered Glucose Metabolism and Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Case Control Study
Background. Diaphanous related formin 1 (DIAPH1) is a novel component of advanced glycation end product (AGE) signal transduction that was recently found to participate in diabetes-related disorders, obesity, and androgen hormones. We investigated whether plasma DIAPH1 levels were a potential prognostic predictor for polycystic ovary syndrome (PCOS). Methods. The levels of circulating plasma DIAPH1 and indicators of glucose, insulin, lipid metabolism, liver enzymes, kidney function, sex hormones, and inflammation were measured in 75 patients with PCOS and 77 healthy participants. All of the participants were divided into normal-weight (NW) and overweight/obese (OW) subgroups. Statistical analyses were performed with R studio. Results. PCOS patients manifested hyperandrogenism, increased luteinizing hormone/follicle-stimulating hormone (LH/FSH), and accumulated body fat and insulin resistance. Plasma DIAPH1 levels were significantly decreased in women with PCOS compared to control participants, and DIAPH1 levels were distinctly reduced in OW PCOS compared to OW control subjects ( ). DIAPH1 levels correlated with fasting blood glucose (FBG), total cholesterol (TC), the homeostasis model assessment of β-cell function (HOMA-β), and LH/FSH in all participants (FBG: , ; TC: , ; HOMA-β: , ; LH/FSH: , ). Multivariate logistic regression analysis revealed that plasma DIAPH1 levels were an independent risk factor for PCOS. A model containing DIAPH1, BMI, FBG, and testosterone was constructed to predict the risk of PCOS, with a sensitivity of 92.0% and a specificity of 80.9%. A nomogram was constructed to facilitate clinical diagnosis. Conclusions. These findings suggest the association of plasma DIAPH1 with glucose metabolism, insulin resistance, and sex hormones and support DIAPH1 as a potential predictive factor for PCOS.
- Open Access
- 3 May 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (11) , 5305-5315
mGPDH Deficiency leads to melanoma metastasis via induced NRF2
Oxidative stress critically influences carcinogenesis and the progression of melanoma, and aggressive malignant melanoma activity is due to its high metastatic ability. Some findings in several cancer cell lines have indicated that mGPDH, a component of the mitochondrial respiratory chain, also modulates oxidative stress. However, the role of mGPDH in melanoma remains elusive. Here, we report that the mGPDH protein level is decreased in human skin melanoma compared to normal skin and decreased in metastatic melanoma compared to primary melanoma. Our in vivo and in vitro experiments indicated that mGPDH depletion accelerated melanoma migration and invasion without affecting proliferation or apoptosis. Mechanistically, we found elevated NRF2 protein levels in human skin melanoma and mGPDH‐knockout (ko) metastatic xenografts in the lungs of nude mice. Moreover, in A375 melanoma cells, the loss of mGPDH‐induced NRF2 expression but did not affect NRF2 protein degradation. Additionally, melanoma metastasis induced by the loss of mGPDH was rescued by the further down‐regulation of NRF2 in vivo and in vitro. Consistently, mGPDH overexpression (oe) depressed NRF2 expression and attenuated the malignant properties of melanoma cells. In conclusion, our findings suggest that mGPDH suppresses melanoma metastasis by inhibiting NRF2 and downstream oxidative signals, highlighting the therapeutic potential of mGPDH for melanoma treatment.
- 3 May 2021
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (11) , 5305-5315
Open AccessmGPDH Deficiency leads to melanoma metastasis via induced NRF2
Oxidative stress critically influences carcinogenesis and the progression of melanoma, and aggressive malignant melanoma activity is due to its high metastatic ability. Some findings in several cancer cell lines have indicated that mGPDH, a component of the mitochondrial respiratory chain, also modulates oxidative stress. However, the role of mGPDH in melanoma remains elusive. Here, we report that the mGPDH protein level is decreased in human skin melanoma compared to normal skin and decreased in metastatic melanoma compared to primary melanoma. Our in vivo and in vitro experiments indicated that mGPDH depletion accelerated melanoma migration and invasion without affecting proliferation or apoptosis. Mechanistically, we found elevated NRF2 protein levels in human skin melanoma and mGPDH‐knockout (ko) metastatic xenografts in the lungs of nude mice. Moreover, in A375 melanoma cells, the loss of mGPDH‐induced NRF2 expression but did not affect NRF2 protein degradation. Additionally, melanoma metastasis induced by the loss of mGPDH was rescued by the further down‐regulation of NRF2 in vivo and in vitro. Consistently, mGPDH overexpression (oe) depressed NRF2 expression and attenuated the malignant properties of melanoma cells. In conclusion, our findings suggest that mGPDH suppresses melanoma metastasis by inhibiting NRF2 and downstream oxidative signals, highlighting the therapeutic potential of mGPDH for melanoma treatment.
- Open Access
- 1 June 2019
- Published by Elsevier in EBioMedicine
- Vol. 44, 665-674
Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis
- 1 June 2019
- Published by Elsevier in EBioMedicine
- Vol. 44, 665-674
Open AccessAlteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis
- Open Access
- 6 November 2018
- Published by Wiley in Mediators of Inflammation
- Vol. 2018, 1-12
Plasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases
Asprosin is a white adipose tissue-derived hormone that increases abnormally in mammals with insulin resistance. However, the role of asprosin in polycystic ovary syndrome (PCOS), a disease partly characterized by insulin resistance, and its potential connection with type 2 diabetes mellitus (T2DM) and PCOS has not been thoroughly elucidated to date. To investigate the association of asprosin with metabolic profiles, sex-related hormones, or inflammation in females with T2DM or PCOS, plasma asprosin and metabolic indicators were measured in 66 healthy females, 53 female patients with T2DM, and 41 patients with PCOS. Spearman’s correlation analysis and binary logistic regression analysis models were used. Plasma asprosin was significantly higher in T2DM females than in healthy subjects () and was positively correlated with fasting blood glucose (FBG), hemoglobin A1c (HbA1c), and HOMA-IR (). Asprosin in PCOS subjects was also higher than in healthy subjects () but lower than in T2DM subjects (), and it was positively correlated with FBG, HbA1c, HOMA-IR, LDL-c, APOB, APOE, and testosterone (). The BMI-categorized subgroups of PCOS subjects also showed correlations of asprosin with metabolic profiles and sex-related hormones. Binary logistic regression analysis revealed that plasma asprosin level acted as an independent risk factor for T2DM or PCOS. These findings suggest the correlation of plasma asprosin level with glucose metabolism, lipid metabolism, sex-related hormones, and inflammation in females, supporting asprosin as a potential predictive factor for females with metabolic-related diseases. This trial is registered with ChiCTR-ROC-17010719.- 6 November 2018
- Published by Wiley in Mediators of Inflammation
- Vol. 2018, 1-12
Open AccessPlasma Asprosin Levels Are Associated with Glucose Metabolism, Lipid, and Sex Hormone Profiles in Females with Metabolic-Related Diseases
Asprosin is a white adipose tissue-derived hormone that increases abnormally in mammals with insulin resistance. However, the role of asprosin in polycystic ovary syndrome (PCOS), a disease partly characterized by insulin resistance, and its potential connection with type 2 diabetes mellitus (T2DM) and PCOS has not been thoroughly elucidated to date. To investigate the association of asprosin with metabolic profiles, sex-related hormones, or inflammation in females with T2DM or PCOS, plasma asprosin and metabolic indicators were measured in 66 healthy females, 53 female patients with T2DM, and 41 patients with PCOS. Spearman’s correlation analysis and binary logistic regression analysis models were used. Plasma asprosin was significantly higher in T2DM females than in healthy subjects () and was positively correlated with fasting blood glucose (FBG), hemoglobin A1c (HbA1c), and HOMA-IR (). Asprosin in PCOS subjects was also higher than in healthy subjects () but lower than in T2DM subjects (), and it was positively correlated with FBG, HbA1c, HOMA-IR, LDL-c, APOB, APOE, and testosterone (). The BMI-categorized subgroups of PCOS subjects also showed correlations of asprosin with metabolic profiles and sex-related hormones. Binary logistic regression analysis revealed that plasma asprosin level acted as an independent risk factor for T2DM or PCOS. These findings suggest the correlation of plasma asprosin level with glucose metabolism, lipid metabolism, sex-related hormones, and inflammation in females, supporting asprosin as a potential predictive factor for females with metabolic-related diseases. This trial is registered with ChiCTR-ROC-17010719. - 18 December 2017
- Published by American Diabetes Association in Diabetes
- Vol. 67 (3) , 518-531
DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring
Patients with diabetes often experience multiple disease complications. Hypoglycemic agents can have both positive and negative effects on diabetic complications, which should be carefully assessed when developing personalized treatment strategies. Herein, we report that dipeptidyl peptidase-4 inhibitors (DPP-4i), a group of widely used antihyperglycemic agents, can improve diabetic wound healing, independent of their beneficial effects on glycemic control. In particular, DPP-4i promoted the migration and epithelial-mesenchymal transition (EMT) of keratinocytes both directly, and indirectly by inducing SDF-1α production of fibroblasts in vitro and in diabetic mice. In addition, DPP-4i attenuated collagen synthesis and deposition, which may diminish scar formation. Furthermore, the results of a randomized clinical trial (NCT02742233) involving 67 patients with type 2 diabetes supported the role of DPP-4i treatment in diabetic wound healing. Our findings support the application of DPP-4i as a preferred option for treating diabetic patients with ulcers.
- 18 December 2017
- Published by American Diabetes Association in Diabetes
- Vol. 67 (3) , 518-531
DPP-4 Inhibitors Improve Diabetic Wound Healing via Direct and Indirect Promotion of Epithelial-Mesenchymal Transition and Reduction of Scarring
Patients with diabetes often experience multiple disease complications. Hypoglycemic agents can have both positive and negative effects on diabetic complications, which should be carefully assessed when developing personalized treatment strategies. Herein, we report that dipeptidyl peptidase-4 inhibitors (DPP-4i), a group of widely used antihyperglycemic agents, can improve diabetic wound healing, independent of their beneficial effects on glycemic control. In particular, DPP-4i promoted the migration and epithelial-mesenchymal transition (EMT) of keratinocytes both directly, and indirectly by inducing SDF-1α production of fibroblasts in vitro and in diabetic mice. In addition, DPP-4i attenuated collagen synthesis and deposition, which may diminish scar formation. Furthermore, the results of a randomized clinical trial (NCT02742233) involving 67 patients with type 2 diabetes supported the role of DPP-4i treatment in diabetic wound healing. Our findings support the application of DPP-4i as a preferred option for treating diabetic patients with ulcers.
- 1 November 2017
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 28 (11) , 818-830
Multifunctional p62 Effects Underlie Diverse Metabolic Diseases
- 1 November 2017
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 28 (11) , 818-830
Multifunctional p62 Effects Underlie Diverse Metabolic Diseases